GB Patent

GB9927444D0 — Inhibiting gene expression

Assigned to Cancer Research Campaign Technology Ltd · Expires 2000-01-19 · 26y expired

What this patent protects

The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA).

USPTO Abstract

The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA).

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: GB9927444D0
Jurisdiction: GB
Classification: —
Expires: 2000-01-19
Drug substance claim: No
Drug product claim: No
Assignee: Cancer Research Campaign Technology Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.